Introduction
Myorisan, with the National Drug Code (NDC) 61748-303, is a liquid-filled oral capsule containing the active ingredient isotretinoin. It is used primarily for the treatment of severe acne and is labeled and distributed by VersaPharm, Inc.[1].
Market Context
The pharmaceutical market is experiencing significant changes and challenges, including rising drug prices and the impact of various pricing programs.
Drug Price Inflation
According to Vizient's summer Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals is projected to be 3.81% in 2025. This inflation is partly driven by the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[2].
340B Drug Pricing Program
The 340B Drug Pricing Program, which allows hospitals to purchase certain outpatient drugs at discounted prices, also plays a crucial role in the market. This program can offer discounts ranging from 25% to 50% or more on brand-name drugs, depending on the price increases relative to inflation[3].
Pricing Dynamics of Myorisan
Current Pricing
Myorisan, as a generic version of isotretinoin, is subject to market forces that influence its pricing. The active ingredient strength of Myorisan is 30 mg per capsule, and its pricing is influenced by the broader market trends for retinoids and dermatological treatments[1].
Impact of Inflation
Given the projected drug price inflation rate of 3.81% for 2025, it is likely that the price of Myorisan will increase accordingly. However, the exact magnitude of this increase will depend on various factors, including the specific market conditions for isotretinoin and the competitive landscape.
Discounts and Rebates
For hospitals and healthcare providers participating in the 340B program, the price of Myorisan could be significantly lower due to the discounted rates offered under this program. The average 340B discount for a drug can range between 25% and 50%, which could substantially reduce the cost of Myorisan for eligible providers[3].
Market Trends and Projections
Specialty Drugs
The market for specialty drugs, which includes many dermatological treatments, is experiencing rapid growth. The specialty drug market is expected to grow at an annual rate of about 13.5% from 2022 to 2027, driven by the increasing use of high-cost therapies for conditions such as cancer and rare diseases[3].
Outpatient Care Shift
There is a significant shift in the site of care from inpatient to outpatient settings, which affects the demand and pricing of drugs like Myorisan. Outpatient departments and ambulatory surgery centers are projected to see patient growth, leading to increased demand for outpatient drugs[3].
Price Projections
Short-Term Projections
For 2025, considering the overall drug price inflation rate of 3.81%, the price of Myorisan is likely to increase by a similar percentage. However, this increase could be mitigated for providers participating in the 340B program due to the discounted rates.
Long-Term Projections
In the long term, the price of Myorisan will be influenced by broader market trends, including the growth in specialty drugs and the ongoing impact of the 340B program. As the market continues to evolve, with more drugs experiencing high price increases, the discounts offered under the 340B program may become even more critical for managing costs.
Key Takeaways
- Market Inflation: The overall drug price inflation rate is projected to be 3.81% in 2025, which will likely affect the pricing of Myorisan.
- 340B Discounts: Providers participating in the 340B program can expect significant discounts on Myorisan, ranging from 25% to 50% or more.
- Specialty Drug Growth: The rapid growth in the specialty drug market will continue to drive demand and pricing for drugs like Myorisan.
- Outpatient Care: The shift to outpatient care will increase the demand for drugs used in these settings.
FAQs
-
What is the primary use of Myorisan?
Myorisan is primarily used for the treatment of severe acne.
-
Who distributes Myorisan?
Myorisan is distributed by VersaPharm, Inc.
-
What is the projected drug price inflation rate for 2025?
The projected drug price inflation rate for 2025 is 3.81% according to Vizient's summer Pharmacy Market Outlook.
-
How does the 340B program affect the pricing of Myorisan?
The 340B program allows eligible providers to purchase Myorisan at discounted rates, ranging from 25% to 50% or more.
-
What is the expected growth rate of the specialty drug market?
The specialty drug market is expected to grow at an annual rate of about 13.5% from 2022 to 2027.
Sources
- FDA.report - NDC 61748-303 Oral Capsule, Liquid Filled Myorisan.
- Vizient Inc. - Vizient projects drug price inflation at 3.81%.
- American Hospital Association - The 340B Drug Pricing Program.
- FDA - National Drug Code Directory.
- ASPE - HHS.gov - Medicare Drug Price Negotiation Program.
